LCLyndon A. M. Cornelius

Lyndon A. M. Cornelius

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lyndon A. M. Cornelius has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Amy A. Sarjeant

    Materials Science & Engineering, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903, United States

    3 shared publications
  • Arvind Mathur

    Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States

    3 shared publications
  • Darpandeep Aulakh

    Materials Science & Engineering, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903, United States

    3 shared publications
  • James Kempson

    Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States

    3 shared publications
  • Joseph Pawluczyk

    Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States

    3 shared publications
  • Dauh-Rurng Wu

    Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States

    2 shared publications

Latest Publications

  • A Stereocontrolled Synthesis of a Phosphorothioate Cyclic Dinucleotide-Based STING Agonist

    by James Kempson, Huiping Zhang, Xiaoping Hou, Lyndon Cornelius, Rulin Zhao, Bei Wang, Zhenqiu Hong, Martins S. Oderinde, Joseph Pawluczyk, Dauh-Rurng Wu, et al.

    We describe a stereodefined synthesis of the newly identified non-natural phosphorothioate cyclic dinucleotide (CDN) STING agonist, BMT-390025. The new route avoids the low-yielding racemic approach using P(III)-based reagents, and the stereospecific assembly of the phosphorothioate linkages are forged via the recently invented P(V)-based platform of the so-called PSI (Ψ) reagent system. This P(V) approach allows for the complete control of chirality of the P-based linkages and enabled conclusive evidence of the absolute configuration. The new approach offers robust procedures for preparing the stereodefined CDN in eight steps starting from advanced nucelosides, with late-stage direct drop isolations and telescoped steps enabling an efficient scale-up that proceeded in an overall 15% yield to produce multigram amounts of the CDN.


  • Photocatalytic Dearomative Intermolecular [2 + 2] Cycloaddition of Heterocycles for Building Molecular Complexity

    by Martins S. Oderinde, Antonio Ramirez, T. G. Murali Dhar, Lyndon A. M. Cornelius, Christine Jorge, Darpandeep Aulakh, Bhupinder Sandhu, Joseph Pawluczyk, Amy A. Sarjeant, Nicholas A. Meanwell, et al.

    Indole and indoline rings are important pharmacophoric scaffolds found in marketed drugs, agrochemicals, and biologically active molecules. The [2 + 2] cycloaddition reaction is a versatile strategy for constructing architecturally interesting, sp3-rich cyclobutane-fused scaffolds with potential applications in drug discovery programs. A general platform for visible-light mediated intermolecular [2 + 2] cycloaddition of indoles with alkenes has been realized. A substrate-based screening approach led to the discovery of tert-butyloxycarbonyl (Boc)-protected indole-2-carboxyesters as suitable motifs for the intermolecular [2 + 2] cycloaddition reaction. Significantly, the reaction proceeds in good yield with a wide variety of both activated and unactivated alkenes, including those containing free amines and alcohols, and the transformation exhibits excellent regio- and diastereoselectivity. Moreover, the scope of the indole substrate is very broad, extending to previously unexplored azaindole heterocycles that collectively afford fused cyclobutane containing scaffolds that offer unique properties with functional handles and vectors suitable for further derivatization. DFT computational studies provide insights into the mechanism of this [2 + 2] cycloaddition, which is initiated by a triplet–triplet energy transfer process. The photocatalytic reaction was successfully performed on a 100 g scale to provide the dihydroindole analog.


  • Synthesis of 1-(tert-Butyl) 4-Methyl (1R,2S,4R)-2-Methylcyclohexane-1,4-dicarboxylate from Hagemann’s tert-Butyl Ester for an Improved Synthesis of BMS-986251

    by Lyndon A. M. Cornelius, Jianqing Li, Daniel Smith, Subramaniam Krishnananthan, Shiuhang Yip, Dauh-Rurng Wu, Joseph Pawluczyk, Darpandeep Aulakh, Amy A. Sarjeant, James Kempson, et al.

    We describe an efficient synthetic route to differentially protected diester, 1-(tert-butyl) 4-methyl (1R,2S,4R)-2-methylcyclohexane-1,4-dicarboxylate (+)-1, via palladium-catalyzed methoxycarbonylation of an enol triflate derived from a Hagemann’s ester derivative followed by a stereoselective Crabtree hydrogenation. Diester 1 is a novel chiral synthon useful in drug discovery and was instrumental in the generation of useful SAR during a RORt inverse agonist program. In addition, we describe a second generation synthesis of the clinical candidate BMS-986251, using diester 1 as a critical component.was instrumental in the generation of useful SAR during a RORt inverse agonist program. In addition, we describe a second generation synthesis of the clinical agent BMS-986251, using diester 1 as a critical component.